Management of Prostatitis

Diagnosis and Presentation

• Elderly patients with prostatitis may present atypically with altered mental status, functional decline, or falls, rather than classic symptoms of fever, chills, dysuria, and pelvic pain 1

Treatment Recommendations

• The European Urology guidelines recommend avoiding fluoroquinolones in elderly patients with prostatitis due to higher risk of adverse effects, potential drug interactions with polypharmacy, and impaired kidney function concerns 1
• For elderly patients, trimethoprim-sulfamethoxazole or doxycycline (100 mg twice daily) are preferred alternative antibiotics for bacterial prostatitis 1
• Initial antibiotic therapy with piperacilina-tazobactam, ceftriaxona, or ciprofloxacino for 2-4 weeks is recommended, with a success rate of 92-97% in patients with acute bacterial prostatitis, as suggested by the European Association of Urology 2
• The following table summarizes recommended antibiotic regimens for acute bacterial prostatitis:

3

• Specific treatment regimens for atypical pathogens include:
• The American Urological Association recommends isoniazid and rifampicin orally for three months, plus quinolones and cortisol for granulomatous prostatitis 5

Medication Management

• Medication management for elderly patients with prostatitis should include checking for drug interactions with existing medications, adjusting dosages based on renal function, and monitoring for adverse effects more closely 1
• Alpha-blockers, such as Alfuzosin, doxazosin, tamsulosin, or terazosin, are recommended for the treatment of chronic prostatitis, with longer duration of therapy being more effective in alpha-blocker-naïve patients, according to the American Urological Association 6
• Amitriptyline, with Grade B evidence, can be started at low doses (10 mg) and titrated gradually to 75-100 mg if tolerated, for the treatment of CP/CPPS 7
• Cimetidine, with Grade B evidence, has been shown to improve symptoms, pain, and nocturia with minimal side effects in patients with CP/CPPS 7
• Hydroxyzine, with Grade C evidence, may be particularly effective in patients with systemic allergies 7
• Pentosan polysulfate, with Grade B evidence, is FDA-approved for interstitial cystitis/bladder pain syndrome and requires monitoring for macular damage with ophthalmologic exams 7

Non-Pharmacological Management

• Non-infectious prostatitis/CP/CPPS requires a multimodal therapeutic approach, including behavioral modifications, pharmacotherapy, and physical therapy, as recommended by the American Urological Association 7
• Lifestyle modifications, such as weight loss, regular physical exercise, and smoking cessation, may help improve overall health and reduce symptoms 3
• Pelvic floor muscle relaxation, focusing on relaxation rather than strengthening exercises, can help alleviate symptoms in patients with CP/CPPS 8
• Manual physical therapy targeting pelvic floor muscles should be offered to patients with pelvic floor tenderness, including techniques such as releasing muscular trigger points, lengthening muscle contractures, and myofascial release 8
• Self-care practices and behavioral modifications, including dietary changes, elimination diet, fluid management, heat or cold application, and pelvic floor muscle relaxation, are recommended by the American Urological Association 7
• Stress management techniques, such as meditation and imagery, can help manage stress-induced symptom exacerbations in patients with CP/CPPS 7

Monitoring and Follow-up

• Clinical reassessment after 2 weeks and urine culture at the end of treatment are recommended to monitor treatment response, with consideration of PSA measurement 3 months after resolution if elevated during infection 9, 2
• The NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) and the AUA Symptom Index/International Prostate Symptom Score (IPSS) are recommended for quantifying symptoms and monitoring treatment response, according to the American Urological Association 6
• Antimicrobial prophylaxis is strongly recommended for all patients undergoing transrectal prostate biopsy, as this procedure is a significant risk factor for acute bacterial prostatitis, according to the European Association of Urology 2, 10
• Patient education about the chronic nature of the condition and realistic expectations for symptom control is essential for effective management of CP/CPPS 7
• Patients should be informed about the possibility of needing intermittent self-catheterization post-treatment and the importance of follow-up care 8